Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1

In this study, we investigated if Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, augments endometrial cancer (EC) therapy with medroxyprogesterone acetate (MPA). Combined treatment with Gefitinib plus MPA decreased the proliferation and invasiveness of the Ishikawa and RL952 EC cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yuan, Zhou, Jingyi, Li, Xiaoping, Zhao, Lijun, Cheng, Yuan, Lin, Yanying, Wang, Jiaqi, Wei, Lihui, Dong, Yafeng, Wang, Jianliu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777777/
https://www.ncbi.nlm.nih.gov/pubmed/29383165
http://dx.doi.org/10.18632/oncotarget.23264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777777/
https://www.ncbi.nlm.nih.gov/pubmed/29383165
http://dx.doi.org/10.18632/oncotarget.23264

Ejemplares similares